Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer
Completed
National Naval Medical Center
Phase 1
2004-01-01
RATIONALE: Biological therapies, such as imiquimod cream, work in different ways to stimulate
the immune system and stop tumor cells from growing.
PURPOSE: This randomized phase I trial is studying how well imiquimod cream works in treating
patients with basal cell skin cancer.
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
Completed
American Society of Clinical Oncology
Phase 1
2005-08-24
This was a Phase 1, single-arm, open-label, pilot study of NY-ESO-1 protein vaccination with
imiquimod as an adjuvant in patients with resected Stage IIB, IIC, and III malignant
melanoma. The primary study objective was to determine the safety of NY-ESO-1
protein/imiquimod treatment, and the secondary objective was to evaluate the immunogenicity
of treatment.
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
Completed
Cancer Research Institute (CRI)
Phase 1
2005-08-24
This was a Phase 1, single-arm, open-label, pilot study of NY-ESO-1 protein vaccination with
imiquimod as an adjuvant in patients with resected Stage IIB, IIC, and III malignant
melanoma. The primary study objective was to determine the safety of NY-ESO-1
protein/imiquimod treatment, and the secondary objective was to evaluate the immunogenicity
of treatment.
NY-ESO-1 Protein Vaccine With Imiquimod in Melanoma (Adjuvant Setting)
Completed
Ludwig Institute for Cancer Research
Phase 1
2005-08-24
This was a Phase 1, single-arm, open-label, pilot study of NY-ESO-1 protein vaccination with
imiquimod as an adjuvant in patients with resected Stage IIB, IIC, and III malignant
melanoma. The primary study objective was to determine the safety of NY-ESO-1
protein/imiquimod treatment, and the secondary objective was to evaluate the immunogenicity
of treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.